跳转至内容
Merck
CN

860478P

Avanti

cis-4-methylsphingosine

Avanti Research - A Croda Brand

别名:

5-Nonadecene-1,4-diol, 3-amino-5-methyl-, (3R,4S,5Z)-

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H39NO2
分子量:
313.52
MDL编号:
UNSPSC代码:
12352211
NACRES:
NA.25

表单

powder

包装

pkg of 1 × 5 mg (860478P-5mg)

制造商/商品名称

Avanti Research - A Croda Brand

脂质类型

sphingolipids

运输

dry ice

储存温度

−20°C

SMILES字符串

CCCCCCCCCCCCC/C=C(C)\[C@@H](O)[C@@H](N)CO

InChI

1S/C19H39NO2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-17(2)19(22)18(20)16-21/h15,18-19,21-22H,3-14,16,20H2,1-2H3/b17-15-/t18-,19+/m0/s1

InChI key

LMJPKTKGCMCPGM-PIIWLPLESA-N

一般描述

cis-4-methylsphingosine (cis-4M-Sph) is a methyl-branched sphingosine analog.

生化/生理作用

cis-4-methylsphingosine (cis-4M-Sph) modulates sphingosine 1 phosphate (S1P) receptor through its metabolite cis-4-methylsphingosine-1-phosphate (cis-4M-S1P). This leads to S1P receptor internalization and desensitization. cis-4M-Sph shows an inhibitory effect on serine palmitoyltransferase activity.

包装

5 mL Amber Glass Screw Cap Vial (860478P-5mg)

法律信息

Avanti Research is a trademark of Avanti Polar Lipids, LLC

储存分类代码

11 - Combustible Solids

WGK

WGK 3

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Michael Ter Braak et al.
Biochemical pharmacology, 81(5), 617-625 (2010-12-18)
Sphingosine-1-phosphate (S1P) acts as high affinity agonist at specific G-protein-coupled receptors, S1P(1-5), that play important roles e.g. in the cardiovascular and immune systems. A S1P receptor modulating drug, FTY720 (fingolimod), has been effective in phase III clinical trials for multiple
G van Echten-Deckert et al.
The Journal of biological chemistry, 272(25), 15825-15833 (1997-06-20)
The effect of six different structurally modified sphingosine analogues on biosynthesis of sphingolipids was studied in primary cultured murine cerebellar neurons. Treatment of cells with cis-4-methylsphingosine at micromolar levels resulted in a markedly decreased sphingolipid biosynthesis, whereas the other compounds
Wenzheng Xia et al.
Molecular medicine reports, 16(5), 7039-7047 (2017-09-14)
Mesenchymal stem cell (MSC)‑based therapies have demonstrated efficacy in animal models of cardiovascular diseases. However, MSCs decrease in quantity and quality with age, which reduces their capacity for damage repair. Long noncoding (lnc) RNAs regulate gene transcription and the fate
Qun Li et al.
International journal of molecular medicine, 42(2), 1054-1063 (2018-05-12)
Stroke is the second most common cause of death worldwide, and thus, it imposes great financial burdens on both individuals and society. Mesenchymal stem cell (MSC) therapy is a promising approach for ischemic brain injury. However, MSC treatment potential is

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门